Lonza Group Ltd (LZAGY)

About Lonza Group Ltd

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Headquarters: Basel · Employees: 20000 · Website: https://www.lonza.com

Product categories

• Biologics CDMO Services

Supply-chain relationships for LZAGY

• ARVINAS, INC. (ARVN) — supplier

Competitors of Lonza Group Ltd

• Samsung Biologics Co., Ltd. (207940.KS)
• WuXi Biologics (2269.HK)

Frequently asked questions about Lonza Group Ltd (LZAGY)

What is Lonza Group Ltd (LZAGY)?

Lonza Group Ltd (LZAGY) is a publicly traded company in the Healthcare sector (Diagnostics & Research). Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.

Who are Lonza Group Ltd's key suppliers and customers?

Macroplane tracks Lonza Group Ltd's (LZAGY) supply chain. Key suppliers include ARVINAS, INC. (ARVN).

Who are Lonza Group Ltd's main competitors?

Competitors of Lonza Group Ltd (LZAGY) tracked by Macroplane include Samsung Biologics Co., Ltd. (207940.KS), WuXi Biologics (2269.HK).